ArticleBMC cancer2025
Characteristics of extracellular vesicle-derived lncRNAs during the progression of HBV-related hepatocellular carcinoma.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Elevated serum TIM4 is associated with disease severity and serves as a potential predictive biomarker in chronic hepatitis B.BMC infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Liver diseases, including hepatitis B virus (HBV) infection, cirrhosis, and hepatocellular carcinoma (HCC), represent significant global health challenges with limited non-invasive biomarkers for early detection. Extracellular vesicles (EVs), enriched with disease-specific RNAs, offer a promising avenue for biomarker discovery. This study characterized EV-derived long non-coding RNAs (lncRNAs) across various stages of liver disease and explored their mechanistic roles. Serum EVs were isolated from 24 participants (5 healthy controls, 5 chronic hepatitis B patients, 5 liver cirrhosis patients, 4 hepatocellular adenoma patients, and 5 HCC patients) using ultracentrifugation and validated by transmission electron microscopy, nanoparticle tracking analysis, and Western blot. High-throughput transcriptome sequencing systematically analyzed RNA expression profiles in EVs across clinical stages, identifying 133 significantly differentially expressed lncRNAs in the HCC group. Multi-step screening and time-series analysis revealed 10 core lncRNAs associated with HCC progression, and a lncRNA-miRNA-mRNA regulatory network (62 nodes, 68 edges) was constructed. Functional enrichment analysis demonstrated involvement in cell proliferation regulation, transmembrane ion transport, cytosol/plasma membrane localization, protein binding, and autophagy/MAPK pathways, while PPI network analysis identified 10 hub genes (e.g., NTRK2, KCNJ10). Validation in an independent plasma cohort confirmed consistent expression patterns of core lncRNAs and downstream genes. The identified HCC-specific lncRNA biomarkers and regulatory network provide theoretical support for developing novel non-invasive liquid biopsy approaches, holding significant promise for early diagnosis and clinical management of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.